Skip to main content
. Author manuscript; available in PMC: 2017 Aug 21.
Published in final edited form as: Clin Cancer Res. 2017 Apr 26;23(16):4919–4928. doi: 10.1158/1078-0432.CCR-16-2656

Table 2.

Molecular characteristics of the six patients harboring a PIK3CA mutation

Case ID Metastatic site AKT (S473) P70S6K (T389) PIK3CA mutation Mutation description
N02-03-003 Liver Low High E542K Helical domaina
N02-03-011 Liver High High C420R Kinase domain
N02-03-012 Liver High High H1047L Kinase domain
N02-03-020 Liver High High H1047Y, E545K Kinase, helical domainb
N02-03-037 Liver Low Low N345K Noncanonical
N02-02-027 Omentum Low Low R1023Q Unknown role

NOTE: Site of metastasis along with the type of mutation and activation of AKT (S473) and downstream substrate p70S6K (T389) are reported for each patient.

a

Concomitant RPTOR and RPS6KB1 amplification.

b

Concomitant RPS6KB1 amplification.